Details of the Drug

General Information of Drug (ID: DM3BVAE)

Drug Name

Obinutuzumab

Synonyms

GA101/RG7159

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Approved	[1]
Small lymphocytic lymphoma	2A82.0	Approved	[2]
Haematological malignancy	2B33.Y	Phase 1	[3]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

L01FA03: Obinutuzumab

L01FA: CD20 (Clusters of Differentiation 20) inhibitors

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 28.4 days [4]
Metabolism: The drug is not metabolised []
Vd: The volume of distribution (Vd) of drug is 3.8 L []

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Obinutuzumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Obinutuzumab and Siponimod.	Multiple sclerosis [8A40]	[6]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Obinutuzumab and Ocrelizumab.	Multiple sclerosis [8A40]	[7]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Obinutuzumab and Ozanimod.	Multiple sclerosis [8A40]	[8]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Obinutuzumab when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[9]
-----------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6941).
2	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e879-e890.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
6	Cerner Multum, Inc. "Australian Product Information.".
7	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
8	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]